1.96
0.24 (13.95%)
| Previous Close | 1.72 |
| Open | 1.78 |
| Volume | 88,779 |
| Avg. Volume (3M) | 42,286 |
| Market Cap | 18,206,186 |
| Price / Book | 1.84 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -11,193.25% |
| Diluted EPS (TTM) | -3.70 |
| Quarterly Revenue Growth (YOY) | -62.40% |
| Total Debt/Equity (MRQ) | 31.69% |
| Current Ratio (MRQ) | 1.69 |
| Operating Cash Flow (TTM) | -31.34 M |
| Levered Free Cash Flow (TTM) | -19.08 M |
| Return on Assets (TTM) | -48.28% |
| Return on Equity (TTM) | -92.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | SAB Biotherapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -1.5 |
| Average | 0.25 |
|
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 21.02% |
| % Held by Institutions | 23.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| First Premier Bank | 31 Dec 2024 | 18,986 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (Chardan Capital, 512.25%) | Buy |
| Median | 9.00 (359.18%) | |
| Low | 7.00 (Leerink Partners, 257.14%) | Buy |
| Average | 9.33 (376.02%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 17 Sep 2025 | 7.00 (257.14%) | Buy | 2.12 |
| Chardan Capital | 08 Aug 2025 | 12.00 (512.24%) | Buy | 2.20 |
| HC Wainwright & Co. | 22 Jul 2025 | 9.00 (359.18%) | Buy | 2.61 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes |
| 07 Aug 2025 | Announcement | SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates |
| 21 Jul 2025 | Announcement | SAB BIO Announces Oversubscribed $175 Million Private Placement |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |